Europe OKs Utah fix for heart defect

New stent closes troubling opening from the inside

Published: Tuesday, July 7, 2009 10:44 p.m. MDT
 |  E-MAIL | PRINT | FONT + - 

A Utah-designed fix for a common heart defect has received approval for use in Europe and other countries. And its creators are hoping to receive an OK for human trials from the U.S. Food and Drug Administration soon.

Salt Lake City-based Coherex Medical announced Wednesday that its FlatStent EF has received CE Mark clearance for use in Europe and elsewhere. It is a new-generation fix that for the first time closes a Patent Foramen Ovale, or PFO, from within the heart defect itself.

"This is the first real new technology in PFO closure in 15 years," said chief medical officer Dr. Randall Jones.

As they followed 90 patients in clinical trials overseas for six months, they documented "good healing" of the defect, Jones said.

A foramen ovale is a tunnel-like opening between the upper heart chambers that helps a fetus breathe in the womb. The tunnel lets blood bypass the lungs — a good thing in the womb that can cause problems outside it. When it fails to close the way it is supposed to at birth, it's called "patent."

As many as 20 percent of adults have a PFO, though many of them will see no ill effects. For others, the result may be dire. PFOs are blamed for a half-million strokes a year and even more migraine headaches.

Story continues below

When people think of hearts and stents, they picture the small rings that keep a blood vessel open. The FlatStent is a different kind of stent, its purpose to adapt to a PFO's unique shape and pull the opening closed. It is made of Ninitol metal and a polyurethane foam sponge that fosters the growth of tissue in and around it, so the device quickly becomes part of the heart and the closure is complete. The device is threaded into place using a catheter in a minimally invasive procedure that is typically done by interventional cardiologists.

Coherex leaders believe the fact that the tunnel is closed from inside will make a difference in terms of complications, compared with older methods, by reducing blood clot formation, damage to the septal wall and more, said chief executive and president Richard J. Linder.

The European clinical trials in Germany, Switzerland and New Zealand also afforded Coherex the opportunity to look at how often the device closed the PFO on the spot, compared with more slowly as healing and integration occurred. Linder and Jones said they saw closure at the time of the implantation procedure 60 percent of the time. They'd heard older devices closed the PFO on the spot between 10 percent and 30 percent of the time.

Coherex officials believe there is a "multibillion dollar annual market" for PFO closure devices.

Coherex is also developing other technologies to tackle different structural heart defects, Linder said.

E-MAIL: lois@desnews.com

Recent comments

Just goes to show the great things companies are doing here in Utah....

John | July 9, 2009 at 12:37 p.m.

Image
Coherex

Coherex' FlatStent is now approved in Europe and other countries. It fixes patent foramen ovale, a heart defect.

previousnext

Latest comments

Hair-pulling raises more questions

There's always a double standard when it comes to BYU and the LDS church....

Long days for BYU interns

is a great career. i have really enjoyed it. it is just so hard for young...

Wow, utefans. It must be tough to eat with all that Bile spewing out of...

i also took care of my angel daughter jeanine johnson for over two years.. i...

Finally an objective UTAH fan. I don't agree with all that you said, but...

Send a plane over for Dee Brown.

Obama salutes Fort Hood victims

The words of the President were really inspiring in the midst of the pain,...

i have read abut alot of faked up attacks on synagogues which turn out to be...

Developer looking to buy RSL share

really???? Go Fire

The Church stated that it was for this legislation as long as it did not...

Advertisements
Advertisement